The AHA today urged the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
 
“We also urge that the policy changes made by the final rule, first published in January 2017, remain substantially unchanged,” AHA said today in comments on the proposed rule. 
 
Facing deadlines for responding to a lawsuit brought by the AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems, HRSA Oct. 31 proposed the regulation to change the effective and compliance date to Jan. 1.
 
In its comments, AHA also urged the agency to make pricing information available to 340B hospitals and other participating providers online through a secure website, which is required by the final rule, “available as soon as possible after the effective date.”
 

Related News Articles

Headline
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…
Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The AHA’s Society for Health Care Strategy & Market Development Oct. 21 announced Dennis S. Jolley, system vice president of strategy and planning at UW…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…